Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term TARP vaccination in prostate cancer
NCT02362464Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- May 2015
- Primary completion
- Mar 2022
- Modality
- Whole Cell Cancer Vaccines, Peptides, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of TARP dendritic cell vaccine in prostate cancer (PCa), sponsored by National Cancer Institute. Started May 2015; status: completed.
02
Drugs
TARP dendritic cell vaccine
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02362464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02362464.